Immune Activation Effects at Different Irradiated Sites and Optimal Timing of Radioimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Real-World Analysis.

IF 3.7 3区生物学 Q1 BIOCHEMICAL RESEARCH METHODS

Biological Procedures Online Pub Date : 2023-09-14 DOI:10.1186/s12575-023-00217-y

Min Wu, Shihao Wu, Yuetong Chen, Liangchao Sun, Jundong Zhou

{"title":"Immune Activation Effects at Different Irradiated Sites and Optimal Timing of Radioimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Real-World Analysis.","authors":"Min Wu, Shihao Wu, Yuetong Chen, Liangchao Sun, Jundong Zhou","doi":"10.1186/s12575-023-00217-y","DOIUrl":null,"url":null,"abstract":"Background: In view of the limited data on radiotherapy (RT) combined with immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), this study aimed to identify the immune activation effect on different sites and the survival outcomes of radioimmunotherapy at different treatment stages.Methods: Forty-five patients diagnosed with ES-SCLC were included in this retrospective analysis. We collected the overall survival (OS) of the patients,, recorded the blood cell counts before, during, and after RT, and derived blood index ratios such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). The datasets were analyzed using the Spearman rank correlation test, Kruskal-Wallis rank sum test and logistic regression.Results: Among the selected blood indices, the delta-NLR/PLR/Sll correlated with different irradiated organs, and the mean ranks of these three indices were the lowest in the brain-irradiated group during immunotherapy. Additionally, adjunct first-line immunotherapy with RT demonstrated a significant improvement compared to second- or third-line therapy and subsequent therapies.Conclusion: Our findings suggest that compared to other organs, the strongest immune activation effect occurs with brain RT, and ES-SCLC patients who received radioimmunotherapy (RIT) earlier achieved higher OS rates.","PeriodicalId":8960,"journal":{"name":"Biological Procedures Online","volume":"25 1","pages":"24"},"PeriodicalIF":3.7000,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503112/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological Procedures Online","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s12575-023-00217-y","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In view of the limited data on radiotherapy (RT) combined with immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), this study aimed to identify the immune activation effect on different sites and the survival outcomes of radioimmunotherapy at different treatment stages.

Methods: Forty-five patients diagnosed with ES-SCLC were included in this retrospective analysis. We collected the overall survival (OS) of the patients,, recorded the blood cell counts before, during, and after RT, and derived blood index ratios such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). The datasets were analyzed using the Spearman rank correlation test, Kruskal-Wallis rank sum test and logistic regression.

Results: Among the selected blood indices, the delta-NLR/PLR/Sll correlated with different irradiated organs, and the mean ranks of these three indices were the lowest in the brain-irradiated group during immunotherapy. Additionally, adjunct first-line immunotherapy with RT demonstrated a significant improvement compared to second- or third-line therapy and subsequent therapies.

Conclusion: Our findings suggest that compared to other organs, the strongest immune activation effect occurs with brain RT, and ES-SCLC patients who received radioimmunotherapy (RIT) earlier achieved higher OS rates.

Abstract Image

查看原文本刊更多论文

广泛期小细胞肺癌患者不同照射部位的免疫激活效应和放射免疫治疗的最佳时机:现实世界分析

背景:鉴于广泛期小细胞肺癌(ES-SCLC)患者放射治疗(RT)联合免疫治疗的资料有限，本研究旨在确定放射免疫治疗在不同部位的免疫激活作用以及不同治疗阶段的生存结局。方法:回顾性分析45例确诊为ES-SCLC的患者。我们收集了患者的总生存期(OS)，记录了放疗前、放疗期间和放疗后的血细胞计数，并得出了中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)和全身免疫炎症指数(SII)等血液指标比率。采用Spearman秩相关检验、Kruskal-Wallis秩和检验和logistic回归对数据集进行分析。结果:所选血液指标中，delta-NLR/PLR/Sll与不同受照器官相关，且免疫治疗期间脑受照组这三项指标的平均排名最低。此外，与二线或三线治疗和后续治疗相比，辅助一线免疫治疗与RT显示显着改善。结论:我们的研究结果表明，与其他器官相比，最强的免疫激活效应发生在脑RT，早期接受放射免疫治疗(RIT)的ES-SCLC患者获得更高的OS率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biological Procedures Online 生物-生化研究方法

CiteScore

10.50

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： iological Procedures Online publishes articles that improve access to techniques and methods in the medical and biological sciences. We are also interested in short but important research discoveries, such as new animal disease models. Topics of interest include, but are not limited to: Reports of new research techniques and applications of existing techniques Technical analyses of research techniques and published reports Validity analyses of research methods and approaches to judging the validity of research reports Application of common research methods Reviews of existing techniques Novel/important product information Biological Procedures Online places emphasis on multidisciplinary approaches that integrate methodologies from medicine, biology, chemistry, imaging, engineering, bioinformatics, computer science, and systems analysis.